secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001193125-25-113299
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Sensei Biotherapeutics Reports Q1 2025 Results; Clinical Progress for Solnerstotug in PD-(L)1 Resistant Tumors
--------------------------------------------------------------------------------

- Net loss of $6.9 million for Q1 2025, down from $8.0 million in Q1 2024.
- Cash, cash equivalents and marketable securities were $34.3 million as of March 31, 2025, expected to fund operations into Q2 2026.
- Dose expansion enrollment complete with 63 patients; full Phase 1/2 data expected by year-end 2025.
- Favorable clinical activity observed in PD-(L)1 resistant 'hot' tumors, with response rates nearly three times higher than typical rechallenge.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312525113299/0001193125-25-113299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312525113299/d923057d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-113299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer